YY/T 1888-2023Recombinant humanized collagen protein (English PDF)
重组人源化胶原蛋白
Open the YY/T 1888-2023 preview as PDF
This is a limited preview
Buy now to download the full PDF (30 pages)
Issued by
NMPA
Level / Type
Industry · Recommended
Issue date
January 18, 2023
Implementation date
July 20, 2023
Scope
YY/T 1888-2023 is the English-translated version of 重组人源化胶原蛋白.
YY/T 1888 is the Chinese standard for recombinant humanized collagen, collagen produced by engineered cells rather than extracted from animal tissue. The point of making it recombinantly is to remove what animal-derived collagen carries with it: viral and prion risk, batch variability, and the immunogenicity of a non-human sequence. This document specifies what such a protein has to be, covering the identity and purity of the material, the characterisation that establishes it, the residuals from the expression system and the labelling. Recombinant collagen is a Chinese industrial strength, used in wound dressings, dermal fillers, tissue scaffolds and cosmetics, and China moved early to standardise it. For a manufacturer or a purchaser of the raw material, this is the specification a Chinese registration and a supply contract refer to.
Document preview — YY/T 1888-2023
National Standard of the People's Republic of China
- ICS
- 11.040.30
- Classification
- C30
Issued by: National Medical Products Administration
Contents
- 1 Scope
- 2 Normative references
- 3 Terms and Definitions
- 4 Quality Control
Foreword
This document is in accordance with the provisions of GB/T 1.1-2020 "Guidelines for Standardization Work Part
1.Structure and Drafting Rules for Standardization Documents" drafting. Please note that some contents of this document may refer to patents. Publishing of this document The Agency assumes no responsibility for identifying patents. This document is proposed by the State Drug Administration. This document is under the jurisdiction of the Medical Device Technology Evaluation Center of the State Food and Drug Administration. This document was drafted by: Fudan University, Sichuan University, Institute of Biophysics, Chinese Academy of Sciences, Second Affiliated Hospital of Chongqing Medical University, Sichuan Medical Device Biomaterials and Products Inspection Center Co., Ltd. (Sichuan Medical Devices Biomaterials and Products Inspection Center), Shaanxi Provincial Food Institute for Drug Control, Shandong Institute for Medical Device and Drug Packaging Inspection, Sichuan Institute for Drug Control (Sichuan Medical Device Testing Center), Shanxi Jinbo Biomedicine Co., Ltd., Jiangsu Chuangjian Medical Technology Co., Ltd., Shanghai Zhongke New Life Biology Co., Ltd. Technology Co., Ltd. The main drafters of this document. Lu Lu, Wang Yunbing, Zhu Yun, Yang Li, Lin Hai, Dong Xiaojing, Liang Jie, Cai Hu, Zhang Min, Liu Xinglan, Wang Jian, Li Haihang, Ruan Hongqiang, Jiang Shibo, Deng Xiang, Wang Changhe, Hou Li, Zhao Daiguo, Yu Yufeng, Fan Xiaoju, Liu Jingtang, Hua Chen. Recombinant Humanized Collagen
1 Scope
YY/T 1888 is the Chinese standard for recombinant humanized collagen, collagen produced by engineered cells rather than extracted from animal tissue. The point of making it recombinantly is to remove what animal-derived collagen carries with it: viral and prion risk, batch variability, and the immunogenicity of a non-human sequence. This document specifies what such a protein has to be, covering the identity and purity of the material, the characterisation that establishes it, the residuals from the expression system and the labelling. Recombinant collagen is a Chinese industrial strength, used in wound dressings, dermal fillers, tissue scaffolds and cosmetics, and China moved early to standardise it. For a manufacturer or a purchaser of the raw material, this is the specification a Chinese registration and a supply contract refer to.
This document specifies the quality control, technical requirements, test methods, stability, biological evaluation and packaging of recombinant humanized collagen. Packing, transportation and storage etc. This document applies to the quality of recombinant humanized collagen that does not contain the amino acid sequence of non-human collagen as a raw material for medical devices control. NOTE. The samples validated in this document are based on recombinant type III humanized collagen raw material. Other recombinant humanized collagen raw materials, if applicable, can be referred to Exam document.
2 Normative references
The contents of the following documents constitute the essential provisions of this document through normative references in the text. Among them, dated references For documents, only the version corresponding to the date is applicable to this document; for undated reference documents, the latest version (including all amendments) is applicable to this document.
GB/T 16886.1 Biological evaluation of medical devices Part
3 Terms and Definitions
YY/T 1849-2022 and the following terms and definitions apply to this document.
3.1 The full-length or partial amino acid sequence fragments encoded by human collagen-specific type genes prepared by DNA recombinant technology, or human collagen-containing A combination of functional fragments of collagen.
3.2 Human collagen types humancolagentypes Genetically, it can be divided into more than 20 different species, which differ in amino acid sequence, molecular assembly form or tissue distribution characteristics.
Note. Different types of human collagen are generally named sequentially by Roman numerals, such as humanTypeIcolagen means human typeIcollagen. each type Human collagen is assembled by one or more collagen genes, for example, human type I collagen is composed of human COL1A1 and COL1A2 genes coded assembly.
3.3 human collagen fragment humancolagenfragment It is an amino acid sequence fragment with a certain continuous length that can form a stable structure within the same amino acid sequence of human collagen.
4 Quality Control
Due to the different human collagen types and amino acid sequence fragments selected for recombinant humanized collagen, and the differences in expression systems, the amino acid sequence and physical and chemical properties are quite different. Used as raw materials for medical devices, it is necessary to establish a suitable method for quality control of products between different batches.
......
This preview omits tables, figures, formulas and parts of the technical clauses. The complete document — 30 pages — is available in the English PDF.
Referenced standards
Normative references
YY/T 1849-2022
Similar standards
YY/T 1897|YY/T 1843|YY/T 1849
How to Buy YY/T 1888-2023
- 1Add to cart. Click the "Buy YY/T 1888-2023" button on this page. You can add more standards before checkout.
- 2Checkout. Enter your email and billing details. Payment is processed securely by Stripe (cards, Apple Pay, Google Pay supported).
- 3Instant delivery (0–9 sec). Delivery is automatic: within seconds of payment you'll receive an email with a secure download link. The link stays valid for 72 hours.
- 4Invoice included. A tax invoice is attached to the confirmation email. Need a custom invoice? Contact us.
Related Standards
GB/T 16886.1-2022 — Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process
GB/T 16886.10-2024 — Biological evaluation of medical devices - Part 10: Tests for skin sensitization
YY/T 0297-2026 — General requirements for clinical investigation of medical devices
Secure payment via Stripe
Payments accepted
YY/T 1888-2023
$275.00